FACIT is a business accelerator and investor established by the Ontario Institute for Cancer Research (OICR) to support the commercialization of Ontario breakthrough cancer innovations that benefit patients, researchers, investors and the province's economy.
Location: Canada, Ontario, Toronto
Employees: 1-10
Founded date: 2014
Investment Type: Accelerator
Investment Stage: Series A
Portfolio 32
| Date | Name | Website | Total Raised | Location |
| 26.04.2023 | cTRL Thera... | ctrl-therapeutics.com | $10M | United Sta... |
| 23.02.2017 | Fusion Pha... | fusionpharma.com | $195.91M | Canada, On... |
| - | health.sunnybrook.ca | - | - | |
| - | Harmonic M... | harmonicmedical.com | - | - |
| - | 404 Page | dbms.queensu.ca | - | - |
| - | Nanology L... | nanologylabs.com | - | Canada, On... |
| - | Radialis M... | rezniklab.lakeheadu.ca | - | - |
| - | Privacy An... | privacy-analytics.com | $3.5M | Canada, On... |
| - | KA Imaging... | kaimaging.com | - | Canada, On... |
| - | Faculty: R... | pharmtox.utoronto.ca | - | - |
Show more
Mentions in press and media 10
| Date | Title | Description |
| 13.09.2024 | Radiant Bio: $35 Million (Series A) Raised For Advancing Antibody Platform | Radiant Biotherapeutics, a preclinical biotechnology company building an antibody platform to deliver transformative therapies for patients facing life-changing disease, announced it has closed a $35 million Series A financing. The Bill &am... |
| 11.09.2024 | Radiant Biotherapeutics Closes $35M Series A Financing | Radiant Biotherapeutics, a Toronto, Canada-based preclinical biotechnology company developing an antibody platform, raised $35M in Series A funding. The round was led by Bill & Melinda Gates Foundation and Amplitude Ventures of Canada. ... |
| 02.07.2019 | Startup competitions seeking companies focused on cancer | They include Freedom from Cancer Startup Challenge and FACIT's Annual Pitch Competition If you're a startup seeking opportunities to get funded, educated or connected, startup competitions are a great resource. Vator has been holding its ow... |
| 09.04.2019 | Nanology Labs receives investment from oncology research fund | Nanology Labs, a pharmaceutical startup based out of the University of Toronto, has received an investment from the FACIT Prospects Oncology Fund, which was designed to advance Ontario’s cancer research innovations by supporting proof-of-co... |
| 22.03.2017 | Propellon Therapeutics Raises $3.0M in Seed Financing | Propellon Therapeutics, a Toronto, Canada-based developer of a portfolio of WDR5-targeted anti-cancer therapeutics, raised $3.0M in seed financing. Fight Against Cancer Innovation Trust (FACIT), which has established Propellon’s WDR5 inhibi... |
| 22.03.2017 | Facit Launches The Prospects Oncology Fund | Toronto, Ontario, Canada-based Fight Against Cancer Innovation Trust (“FACIT”) has launched The Prospects Oncology Fund. The evergreen fund, whose capital is allocated annually, is designed to advance early-stage cancer discoveries by suppo... |
| 29.10.2015 | Today in funding ($51M): Turnstone Biologics, Invixium, Qvella, Elastic Path Software | This week, three Toronto-based companies raised impressive Series A rounds – two of them in healthtech. Here’s the latest on who raised how much, and from whom. Qvella raises $26 million series A Toronto-based Qvella, a leading molecular di... |
| 28.10.2015 | Turnstone Biologics Completes $11.3M Series A Financing Round | Turnstone Biologics Inc., a Toronto, Ontario, Canada-based developer of novel oncolytic viral immunotherapies, completed an $11.3m Series A financing round. The round was led by Versant Ventures with follow-on capital committed in excess of... |
| - | Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B Financing | Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led by Varian and new investo... |
| - | Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments | HAMILTON ONTARIO, February 23, 2017 – Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing... |